High Tide's Record Quarter — A Cannabis Story the Market's Theme Map Can't See

Best quarter in company history as German medical-cannabis hypergrowth and Canadian operating leverage converge, yet cannabis registers nowhere in the market's dominant narrative.

HITI · Earnings Call · 2026-09-15

The quarter where the bottom line finally caught up

High Tide's fiscal Q3 (ended July 31) was, in CEO Raj Grover's framing, “the best quarter in our company's history” — Raj Grover, President and Chief Executive Officer · 2026-09-15 — and for once the superlative holds all the way down the income statement. Revenue printed a fresh new record at CAD 198.8M, up 33% year-over-year, which CFO Mayank Mahajan called “the fastest pace of growth in 13 quarters.” — Mayank Mahajan, Chief Financial Officer · 2026-09-15 Adjusted EBITDA rose 52% to CAD 16.2M (an 8.2% margin, a 12-quarter high), operating income jumped 133% to CAD 8.7M, and net income set a record at CAD 12.7M.

The engine is operating leverage: “60% of the increase in gross margin flowed down to operating income, which was up 43% sequentially and 133% year-over-year.” — Raj Grover, President and Chief Executive Officer · 2026-09-15 Salaries and wages fell to 11.4% of revenue (a 12-quarter low) and G&A to 3.9% (an eight-quarter low). This is the inflection management has promised for years — growth showing up in earnings growth, not just sales. With 2.73M discount Club-style Cabana Club members (+27%) and 186K paid ELITE members (+62%), the loyalty flywheel is doing the work.

Two engines: mature Canada, hypergrowth Germany

Canada is the cash machine: 232 stores, same-store sales flat for the full quarter but positive in June and July, with transaction counts up 1.1% even as peers post negative comps. Grover leaned hard on that share-gain contrast: “We were actually up 1.1% on the transactions... our customers are not leaving us.” — Raj Grover, President and Chief Executive Officer · 2026-09-15 The thinner baskets — customers trading 3.5g bags for ounce bags — are the tell of real consumer stress, not a demand problem.

Germany is the growth story. The medical cannabis distribution segment moved 10.2 tons, up 35% sequentially and 165% above Remexian's pace at acquisition. Revenue of CAD 38.2M rose 21% sequentially while EBITDA grew almost twice as fast, up 38% to CAD 4.4M — a record 12% margin. The more striking number is gross margin: from 12–13% in Q1, to 27% in Q2, to 26% in Q3, as Canadian-scale procurement displaces expensive Portuguese biomass. Grover's summary:

The German market is absolutely on fire, and the demand for Canadian cannabis is tremendous there... Canadian medical cannabis exports to Germany are now approaching almost a CAD 600 million run rate.
Raj Grover, President and Chief Executive Officer · 2026-09-15

What's genuinely new — and the contrast with the tape

Several details are fresh. First, factoring economics: Remexian finances German pharmacy receivables at sub-9% rates, a structural working-capital tool a year into ownership — “We are getting factoring done for sub 9%... the receiving parties, which are the pharmacies in Germany, are really creditworthy.” — Raj Grover, President and Chief Executive Officer · 2026-09-15 Second, UK patience: management explicitly refuses to rush, “we don't want to rush into the U.K. or any other market at any cost.” — Raj Grover, President and Chief Executive Officer · 2026-09-15 Third, the recurring Import quota friction in Germany is framed as seasonal noise.

Here is the interesting part for the market historian: none of this connects to the global theme cluster. The editor-curated global keywords for this quarter are dominated by Net tariff refunds, IEEPA recoveries, AI/data-centre buildouts and energy — and a raft of recent reporters (CULP, DBI, LOVE, M, VNCE, VRA, HOFT, KR) leaned on tariff recoveries to flatter their numbers. High Tide has essentially no tariff exposure, which the company itself flagged back in March 2025 (99% domestically sourced). So its beat is operational, not a one-off import-refund windfall — a genuine point of differentiation against the earnings quality of peers this season. Cannabis, meanwhile, appears nowhere in the global top-75. High Tide is an idiosyncratic story trading alongside a market obsessed with tariffs, compute and power.

A faded theme and a cheap setup

One thing has quietly aged out: the discount-club model that was High Tide's signature theme from 2021 (a top gainer then, momentum 336) is now boilerplate — Grover concedes competitors are “panicking and increasingly starting to copy pieces of our model.” — Raj Grover, President and Chief Executive Officer · 2026-09-15 The moat is shifting from the club itself to procurement scale and the German distribution machine.

The balance sheet backs the story: CAD 7M of free cash flow in the quarter, cash up CAD 10.6M, total debt CAD 60M with a CAD 25M Bank of Montreal revolver undrawn. At a CAD ~212M market cap, management pitches a 5.4x EV/EBITDA on annualized EBITDA — “we see the current setup as more of an opportunity than a risk.” — Raj Grover, President and Chief Executive Officer · 2026-09-15 The prior-quarter's Portuguese-biomass drag (bought at just 3.64x partly because of it) is now clearly behind.

The counterpoint: the company still trades on cannabis-sector sentiment, not its cash flows, and the German quota cycle will bite again next year. But a record quarter, a genuine bottom-line inflection, and themes that sit entirely outside the market's dominant narrative make this a name worth watching for a re-rating the tape hasn't yet granted.